

News Release

Penn Medicine Discovery Could Lead to Fewer Side Effects from a Diabetes Treatment

A mouse study detailed the differences between the two forms of the protein PPARgamma, a target of “glitazone” diabetes drugs, could cut out weight gain side effects

March 10, 2022

By uncovering the subtle difference between two varieties of a protein, researchers from the Perelman School of Medicine at the University of Pennsylvania may have discovered how to eliminate the risk of weight gain from a certain type of diabetes medication. Through this, it's possible that more patients with diabetes could get more effective treatment from modified thiazolidinediones, which many likely avoid in their current form due to side effects. These findings were published in *Genes & Development*.



“One small, undiscovered difference between the two forms of a single protein proved to be extremely significant,” said study senior author **Mitchell Lazar, MD, PhD**, the Willard and Rhoda Ware Professor in Diabetes and Metabolic Diseases at Penn. “Our findings suggest a way to improve on the mechanism of action of thiazolidinedione drugs, which holds promise for eliminating the side effect of weight gain.”

The popularity of diabetes drugs called thiazolidinediones, which are also known as glitazones, has been reduced because of side effects such as weight gain. They work by activating a fat cell protein called PPARgamma (PPAR γ). The protein occurs in two forms, PPAR γ 1 and PPAR γ 2, whose functional differences have been unclear. But when the Penn researchers examined each form of the protein on its own, they found that activating just PPAR γ 2 with a thiazolidinedione drug protects mice from diabetes-like metabolic changes—without causing weight gain.

Type 2 diabetes is characterized by the progressive dysfunction of the insulin hormone signaling system in the body, resulting in chronic, high levels of glucose (sugar) in the blood. This, in turn, contributes to the hardening of arteries, high blood pressure, heart attacks, strokes, and other serious diseases. Thought to arise largely due to obesity, poor

diets, and modern sedentary lifestyles, type 2 diabetes has become epidemic in many countries. The U.S. Centers for Disease Control and Prevention has estimated that, in the United States alone, about 35 million people, roughly 10 percent of the population, are living with the disorder.

Thiazolidinediones, which include rosiglitazone (under the brand name Avandia), were introduced in the 1990s and, for many years, were widely used as diabetes drugs. They have since become less popular due to side effects. This has led some researchers to investigate whether new compounds could be developed that retain these drugs' therapeutic effects while having fewer side effects.

In their study, Lazar and his team approached this problem by taking a closer look at thiazolidinediones' target, PPAR γ , which helps control fat cell production. The scientists studied two lines of mice: One greatly deficient in one form of the protein, PPAR γ 1, the other greatly deficient in PPAR γ 2. In the mice, the scientists showed that activating PPAR γ 1 or PPAR γ 2 with a thiazolidinedione had an anti-diabetic effect in each case, protecting mice from the metabolic harm of a high-fat diet.

However, the researchers discovered that activation of these two forms has subtly different downstream effects on gene activity. Specifically, in the PPAR γ 1-deficient mice (in which most of the present PPAR γ takes the form of PPAR γ 2), the thiazolidinedione treatment caused no weight gain.

The finding therefore suggests that it may be possible to realize the benefits of thiazolidinediones without the weight gain side effect, by activating only PPAR γ 2 and not PPAR γ 1.

"We're now studying in more detail how PPAR γ 1 and PPAR γ 2 work and how they differ, in the hope of finding ways to selectively activate PPAR γ 2," Lazar said.

The research was supported by the American Diabetes Association, the American Heart Association, Cox Medical Institute, the JPB Foundation, and the National Institutes of Health (1-18-PDF-132, 827529, R01-DK049780, R01-DK121801, K01-DK125602).

TOPIC: Endocrinology

Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a \$8.9 billion enterprise.

The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with \$496 million awarded in the 2020 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center—which are recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report—Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nation's first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.

Penn Medicine is powered by a talented and dedicated workforce of more than 44,000 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2020, Penn Medicine provided more than \$563 million to benefit our community.